Efficacy and safety of tezacaftor/ivacaftor in patients (Pts) aged >= 12 years with CF heterozygous for F508del and a residual function mutation: A randomized, double-blind, placebo-controlled, crossover phase 3 study

Authors
Category Primary study
JournalPneumologie
Year 2018
This article has no abstract
Epistemonikos ID: 2dadbe5308528e517834778ef6875bd77f170532
First added on: Feb 09, 2025